Quality of Life in Polycystic Ovary Syndrome After Anti-Androgen Therapy Using PCOSQOL-47 and PCOSQOL-42
March 2026
in “
Endocrine Metabolic & Immune Disorders - Drug Targets
”
TLDR Combined finasteride and spironolactone therapy significantly improves quality of life in women with PCOS.
The study evaluated the impact of combined finasteride and spironolactone on health-related quality of life (HRQOL) in 263 married and 236 unmarried women with PCOS over one year. Significant reductions in testosterone levels, dehydroepiandrosterone sulfate, body mass index (BMI), and modified Ferriman-Gallwey (mFG) scores were observed. Both groups experienced marked HRQOL improvements, with unmarried women showing greater gains. Psychological and emotional domains improved most in married women, while menstrual and fertility domains improved most in unmarried women. The study concludes that this combined therapy significantly enhances HRQOL and reduces hyperandrogenism, supporting its use alongside lifestyle changes.